However, the development of HER2 targeted therapy is mainly against HER2 driving mutations, which is rare and present in about 2–3% of patients, mostly women, never/light smoker, and adenocarcinoma.199, 202. The gene discussed is ERBB2; the disease is adenocarcinoma.